vii
Lifecycle Management Through the Rx-to-OTC Switch
Author Acknowledgments
On behalf of lead editor Robert Falcone and the Editorial Advisory Committee, the Regulatory Affairs
Professionals Society (RAPS) would like to express appreciation to the following subject matter experts
who shared their experience and knowledge by volunteering their time to contribute to the develop-
ment of the first edition of Lifecycle Management Through the Rx-to-OTC Switch: US Considerations and
Perspectives to Advance Self-Care.
Douglas Ws. Bierer, PhD
President, Douglas Bierer Consulting, LLC
US
Chapter 5
Robert Falcone, PhD, FRAPS
Senior Manager, Regulatory Affairs
Prestige Consumer Healthcare
Preface, Chapter 11
Natalie Gauld, DipPharm, MPharm, PhD,
FPS
Access to Medicines Specialist
Natalie Gauld, Ltd.
New Zealand
Chapter 10
Sean Griffin, MBA
Vice President of Regulatory Affairs
Galderma
US
Chapter 8
Edwin L. Hemwall, PhD
Principal
Edwin Hemwall LLC -OTC Drug
Development Consulting Services
US
Chapter 6
Marcia D. Howard, PhD, CAE
Vice President, Regulatory and Scientific Affairs
Consumer Healthcare Products Association
(CHPA)
US
Chapter 1
Barbara A. Kochanowski, PhD
Senior Vice President, Regulatory and Scientific
Affairs
Consumer Healthcare Products Association
(CHPA)
US
Chapter 1
Susan B. Levy
Principal and Founder
Susan B. Levy Consulting, LLC
US
Chapters 2 and 3
Kristie Licata
Vice President: Rx-to-OTC Switch
Bayer Consumer Care
US
Chapter 4
Stephen G. Mann, MBBS (Lond), LRCP,
MRCS, FFPM
Principal Consultant
Stephen Mann Associates Ltd.
UK
Chapter 10